Stent :: Cypher Coronary stents approved for use by Health Canada

Cordis Corporation, the world’s leading drug-eluting stent manufacturer, today announced the launch of CYPHER SELECT(TM) Plus, the first third-generation drug-eluting stent available for the treatment of Canadian patients with coronary artery disease.

This launch coincides with the fifth anniversary of CYPHER Stent, the world’s first drug-eluting stent, in Canada.

“I was very impressed by the deliverability of this third-generation CYPHER SELECT(TM) Plus. I had a complex case involving a very tortuous lesion and found out how easy the Select Plus was sliding throughout the arteries to access the lesion,” said Dr. Erick Schampaert, Head – Division of Cardiology, Hospital Sacre-Coeur de Montreal.

“With this new sirolimus-eluting stent, an interventional cardiologist can now treat challenging lesions. Its innovative delivery technology adds up to its proven safety and efficacy track record.”

Leave a Comment